Daniel J. Lippis, Corporate Vice President for JAPAC at Edwards Lifesciences Corp (NYSE:EW), a medical technology company with a market capitalization of $43.5 billion and an impressive "GREAT" financial health score according to InvestingPro, executed a series of stock transactions as reported in a recent SEC filing. On December 16, 2024, Lippis sold 2,500 shares of Edwards Lifesciences common stock at a weighted average price of $74.08 per share, totaling approximately $185,195. This transaction was part of a pre-established Rule 10b5-1 trading plan adopted on December 11, 2023. The stock, which currently trades near its Fair Value based on InvestingPro analysis, has demonstrated low price volatility and maintains strong fundamentals with a healthy current ratio of 3.46.
In addition to the sale, Lippis exercised stock options to acquire 2,500 shares at a price of $45.28 per share, totaling $113,191. Following these transactions, Lippis holds 23,189 shares directly. The company's management has been actively buying back shares, and with more cash than debt on its balance sheet, Edwards Lifesciences maintains a strong financial position. Discover 8 more exclusive insights and detailed financial analysis with a InvestingPro subscription.
In other recent news, Edwards Lifesciences has seen a series of noteworthy developments. BofA Securities upgraded the company's shares from Neutral to Buy, lifting the price target to $90. This upgrade is based on the company's promising fundamentals, including a 24% revenue growth in the past twelve months. The company's Transcatheter Aortic Valve Replacement (TAVR) technology is seen as a strategic asset, with new growth drivers expected to bolster revenue growth for 2025.
Edwards Lifesciences' annual investor day revealed a promising financial outlook for 2025, with projected revenues ranging from $5.6 billion to $6.0 billion. The company's third-quarter sales saw a 10% increase, reaching $1.35 billion. Growth is anticipated to be driven by the EARLY-TAVR trial, projected to boost the growth of Transcatheter Aortic Valve Replacement procedures. The company's Transcatheter Mitral and Tricuspid Therapies portfolio is expected to generate sales of approximately $2 billion by 2030.
Various analysts have adjusted their stance on the company, with TD Cowen, Truist Securities, and Bernstein SocGen Group maintaining Hold ratings, while RBC Capital Markets maintains an Outperform rating. These ratings reflect the company's strong financial performance and potential for future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.